Joint BioRN & Ci3 Annual Conference 2018: Immunotherapy and beyond - The next generation of cancer treatment

 

 

 

 

October 25, 2018
Merck KGaA, Darmstadt, Germany

Representative: Thomas Hoeger, Ph.D., CEO

Presentation on October 25, 2:55 pm:
Apogenix' TNFR-Mediated Signaling Modulators - Innovative Immuno-Oncology Therapeutics

 

World Immunotherapy Congress 2018

October 29-31, 2018
Basel, Switzerland

Representatives:
Oliver Hill, Ph.D., VP Molecular Biology/Protein Engineering
Juergen Gamer, Ph.D., VP Business Development

Presentation by Dr. Hill on October 30, 3:35 pm:
Hexavalent TNFR-SF Agonists for Cancer Immunotherapy: HERA-CD40L, HERA-CD27L and Beyond



AAPS PharmSci 360 Annual Meeting

November 4-7, 2018
Washington, D.C., USA

Representative: Matthias Schroeder, Ph.D., Senior Scientist Assay Development

 

BIO-Europe

November 5-7, 2018
Copenhagen, Denmark

Representatives:
Thomas Hoeger, Ph.D., CEO
Juergen Gamer, Ph.D., VP Business Development

 

SITC 33rd Annual Meeting

November 7-11, 2018
Washington, D.C., USA

Representative: David Richards, Ph.D., Head of Immunology

Presentation on November 11, 8:05-10:30 am (Session: Next Generation Bispecifics and Antibody-Like Molecules):
Immuno-oncology tHERApy with HERA-GITRL: the novel hexavalent human GITR agonist activates T cells and promotes anti-tumor efficacy independent of Fc-functionality

 

10th Annual PEGS Europe

November 12-16, 2018
Lisbon, Portugal

Representatives:
Oliver Hill, Ph.D., VP Molecular Biology/Protein Engineering
Katharina Billian-Frey, Ph.D., Senior Scientist Molecular Biology/Protein Engineering

Presentation by Dr. Hill on November 15, 4:00 pm:
HERA: Engineering Next-Generation TNFR-SF Agonists for Cancer Immunotherapy

 

SNO 23rd Annual Meeting and Education Day

November 15-18, 2018
New Orleans, LA, USA

Representative: Dr. Harald Fricke, CMO

Poster Presentation: Asunercept plus radiotherapy in relapsed glioblastoma. Update on five years overall survival of study NCT01071837 and development of a Population-PK - Tumor Growth Inhibition - Survival Model

 

European Bioanalysis Forum 11th Open Symposium

November 21-23, 2018
Barcelona, Spain

Representative: Meinolf Thiemann, Ph.D., Director Assay Development

 

ASH 2018

December 1-4, 2018
San Diego, CA, USA

Representative: Dr. Harald Fricke, CMO

 

PepTalk 2019

January 14-18, 2019
San Diego, CA, USA

Representative: Christian Gieffers, Ph.D., VP Analytics/Protein Chemistry

Presentation: Hexavalent Agonists Targeting Co-Stimulatory Receptors of the TNFR-Superfamily for Cancer Immunotherapy